Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Arrowhead Pharmaceuticals, Inc. (ARWR) Profile & Business Summary
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Key Information
| Ticker | ARWR |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://arrowheadpharma.com |
Market Trend Overview for ARWR
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-03-25 (ET)
As of 2026-03-25, ARWR is moving sideways without a clear direction. Over the longer term, the trend remains bullish.
ARWR last closed at 60.77. The price is about 0.4 ATR above its recent average price (58.88), and the market is currently in a sideways market without a clear direction. Price at 60.77 is moving between light support near 60.62 and minor resistance near 64.92. Direction remains unclear. View Support & Resistance from Options
The market is moving sideways, with no clear direction. Both upside and downside risks remain in play.
Trend score: 35 out of 100. Overall alignment is unclear. The market is currently in a sideways market without a clear direction. The longer-term trend is still positive, but short-term signals are not yet confirming it.
There is no clear risk level acting as a key boundary right now.
On 2026-02-12, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-03-16] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is trading 4.0% above the recent estimated cost basis of 58.45, which keeps the recent cost structure in a clearly stronger position. Price is above the main cost band (55.50 to 57.60), and about 77% of recent positioning is already in profit. That supports trend strength, but it also raises the chance of profit-taking if momentum cools. The lower down support area sits around 59.26 to 59.59. It looks more like a first buffer than a major floor. From a trading point of view, the trend still has support, but because the main support sits lower down around 59.26 to 59.59, the key is whether pullbacks remain controlled before dropping back into that zone.
Short Interest & Covering Risk for ARWR
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is within its typical range, with no clear imbalance between buyers and sellers. (Historical percentile: 50%)
Structure Analysis
ARWR Short positioning looks normal. Current days to cover is 5.9 trading days, meaning short positions would unwind somewhat slower than average. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 38/100, DTC percentile 100%) with short positioning continuing to expand and liquidity contracting meaningfully (volume -48%). Positioning is historically elevated, although price and liquidity conditions do not yet confirm structural fragility. Short positioning is at extreme historical levels.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. In the latest reporting period, short interest continues to increase. Average trading volume is weakening, indicating contracting liquidity. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. Rising short pressure is occurring while liquidity is deteriorating. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-02-27 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.